Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-3170
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran) ; volume:22 ; number:12 ; day:21 ; month:10 ; year:2020 ; pages:1-7 ; date:12.2020
Current cardiology reports ; 22, Heft 12 (21.10.2020), 1-7, 12.2020
- Urheber
-
Sinning, David
Landmesser, Ulf
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11886-020-01427-6
- URN
-
urn:nbn:de:101:1-2020122013352696693118
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sinning, David
- Landmesser, Ulf
- SpringerLink (Online service)
Ähnliche Objekte (12)
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Low-density lipoprotein cholesterol lowering treatment: the current approach
Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal
Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Low-density lipoprotein cholesterol lowering treatment: the current approach
Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal
Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Low-density lipoprotein cholesterol lowering treatment: the current approach
Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal
Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice